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BACKGROUND: Aripiprazole is an atypical antipsychotic that
is reported to be effective in the treatment of schizophrenia.
A I M S : To investigate the effects of aripiprazole on patients
with schizophrenia and schizophrenia-like psychoses by
conducting a systematic review of randomized controlled
trials (RCTs). METHOD: Database and manual searches, and
direct contact were used to identify relevant RCTs. RESULTS:
We included 10 randomized controlled studies (involving a
total of 4125 patients), but study attrition was large and the
standard of data reporting was poor. Compared with placebo,
aripiprazole treatment was associated with a significant
decrease in relapse rates, increased compliance with the
study protocol, and a decrease in prolactin levels below the
expected values. Compared with risperidone, aripiprazole
caused less elevation of prolactin levels and less prolongation
of the average QTc interval. CONCLUSIONS: Aripiprazole has
been licensed despite the fact that few reliable data on this
drug are publicly available. It may be effective for treatment
of schizophrenia, but in terms of tolerability and global
outcomes it  shows l itt le di fference f rom exist ing
antipsychotics.
ARIPIPRAZOLE FOR SCHIZOPHRENIA: SYSTEMATIC REVIEW
COMMENTARY
It was initially suggested that aripiprazole may be more effective than other atypical antipsychotics for treatment of
schizophrenia, except clozapine. El-Sayeh et al's systematic review challenges that claim and shows that even though
aripiprazole was more efficacious than placebo, it was no more efficacious than other antipsychotics. While it does produce
less elevation of prolactin and less prolongation of QTc interval (QT interval, corrected for heart rate) than risperidone, it is
not very different from other antipsychotic agents in terms of tolerability and global outcomes. 
Severe mental illness, particularly schizophrenia, has always carried the stigma that mental illness equates violence. This
assumption has been used to justify incarceration of the mentally ill over centuries. The study by Fazel and Grann
challenges that assumption and shows that in Sweden only 5.2% of violent crime was attributable to people with severe
mental illness. The remaining 95% violent crimes were committed by people who did not suffer from severe mental illness.
Although few randomized controlled trials have been conducted to assess the safety of antidepressants in pregnant women,
tricyclic antidepressants (TCAs) and specific serotonin reuptake inhibitors (SSRIs) are generally thought to be safe in
pregnancy. However, the study by Oberlander et al shows that there was an increased risk of low birth weight and
respiratory distress in infants of depressed mothers treated with SSRIs compared to infants of depressed mothers not
treated with SSRIs, even after maternal illness severity was accounted for. 
Syed Ahmer
Assistant Professor of Psychiatry
Aga Khan University Medical College
V O L .  1 ( 3 )   O C T - D E C  2 0 0 6P A K I S T A N  J O U R N A L  O F  N E U R O L O G I C A L  S C I E N C E S  168
Fazel S, Grann M
Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford OX3 7JX, UK. seena.fazel@psych.ox.ac.uk
Am J Psychiatry. 2006 Aug; 163(8):1397-403.
O B J E C T I V E : This study aimed to determine the population
impact of patients with severe mental illness on violent
crime. M E T H O D : Sweden possesses high-quality national
registers for all hospital admissions and criminal convictions.
All individuals discharged from the hospital with ICD
diagnoses of  schizophrenia and other psychoses
(N=98,082) were linked to the crime register to determine
the population-attributable risk of patients with severe
mental illness to violent crime. The attributable risk was
calculated by gender, three age bands (15-24, 25-39, and
40 years and over), and offense type. RESULTS: Over a 13-
year period, there were 45 violent crimes committed per
1,000 inhabitants. Of these, 2.4 were attributable to
patients with severe mental illness. This corresponds to a
population-attributable risk fraction of 5.2%. This attributable
risk fraction was higher in women than men across all age
bands. In women ages 25-39, it was 14.0%, and in women
over 40, it was 19.0%. The attributable risk fractions were
lowest in those aged 15-24 (2.3% for male patients and
2.9% for female patients). C O N C L U S I O N S : The population
impact of patients with severe mental illness on violent
crime, estimated by calculating the population-attributable
risk, varies by gender and age. Overall, the population-
attributable risk fraction of patients was 5%, suggesting that
patients with severe mental illness commit one in 20 violent
crimes.reliable data on this drug are publicly available. It may
be effective for treatment of schizophrenia, but in terms of
tolerability and global outcomes it shows little difference from
existing antipsychotics.
THE POPULATION IMPACT OF SEVERE MENTAL ILLNESS ON VIOLENT CRIME
Oberlander TF, Warburton W, Misri S, Aghajanian J, Hertzman C
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CONTEXT: Prenatal exposure to selective serotonin reuptake
inhibitor (SSRI) antidepressants and maternal depression both
alter neonatal health, and distinguishing the effects of each
influence remains challenging. OBJECTIVE: To determine
whether exposure to SSRIs and depression differs from
exposure to maternal depression alone. DESIGN: U s i n g
population health data, records of neonatal birth outcomes
were linked to records of maternal health and prenatal
maternal prescriptions for SSRIs. S E T T I N G : Population of
British Columbia, Canada. P A R T I C I P A N T S : Mothers and their
infants, representing all live births during a 39-month period
(N = 119,547) (1998-2001). MAIN OUTCOME
M E A S U R E S : Outcomes from infants of depressed mothers
treated with SSRIs (SE-D) were compared with outcomes
from infants of depressed mothers not  treated with
medication (DE) and non-exposed controls. To control for
maternal mental illness severity, propensity score matching
was used to identify a comparison group of DE mothers who
were similar to the SE-D mothers in characteristics in the year
preceding and during pregnancy. RESULTS: Fourteen percent
of mothers were diagnosed as having depression during their
pregnancy, and the incidence of prenatal SSRI exposure
increased from 2.3% to 5.0% during a 39-month period. Birth
weight and gestational age for SE-D infants were significantly
less than for DE infants, as was the proportion of infants born
at less than 37 weeks (95% confidence interval [CI], -1 to -
64, -0.25 to -0.45, and -0.009 to -0.04, respectively),
although differences in the incidence of birth weight less than
the 10th percentile for gestational age were not significant.
An increased proportion of SE-D infants had neonatal
respiratory distress (13.9% vs. 7.8%), jaundice (9.4% vs.
7.5%), and feeding problems (3.9% vs. 2.4%) compared with
DE infants (95% CI of difference, 0.042-0.079, 0.003-
0.334, and 0.005-0.025, respectively). When outcomes
were compared between SE-D and propensity score-matched
DE neonates, SE-D was associated with increased incidence
of birth weight below the 10th percentile and rates of
respiratory distress. C O N C L U S I O N : With linked population
health data and propensity score matching, prenatal SE-D
exposure was associated with an increased risk of low birth
weight and respiratory distress, even when maternal illness
severity was accounted for.
NEONATAL OUTCOMES AFTER PRENATAL EXPOSURE TO SELECTIVE SEROTONIN REUPTAKE
INHIBITOR ANTIDEPRESSANTS AND MATERNAL DEPRESSION USING POPULATION BASED
HEALTH DATA
